ABSTRACT
Primary cutaneous CD30+ large cell lymphoma is an unusual tumor most commonly seen in adults. Most of these lymphomas are of T-cell origin and carry a good prognosis. We present the case of a 4-year-old girl with stage IEA CD30+ large cell lymphoma with a CD56+ natural killer cell phenotype and the t(2;5)(p23;q35) translocation. After excision, the patient has been free of disease for 44 months. Primary cutaneous CD30+ large cell lymphoma is uncommon in children. To our knowledge, primary cutaneous CD30+ natural killer type lymphoma has not been reported previously. The indolent behavior of this tumor indicates its similarity to other primary cutaneous CD30+ large cell lymphomas and its difference from other CD56+ lymphomas involving the skin, which often exhibit an aggressive clinical course. Cases such as this one illustrate why the use of a single, or even a few, immunohistochemical stains can be misleading in regard to lymphoma classification and prognostication.
Subject(s)
Chromosomes, Human, Pair 2/genetics , Chromosomes, Human, Pair 5/genetics , Killer Cells, Natural/pathology , Lymphoma, Large-Cell, Anaplastic/pathology , Skin Neoplasms/pathology , Translocation, Genetic , Antigens, Neoplasm/analysis , Child, Preschool , DNA, Neoplasm/analysis , Female , Humans , Immunoenzyme Techniques , Ki-1 Antigen/analysis , Lymphoma, Large-Cell, Anaplastic/genetics , Phenotype , Polymerase Chain Reaction , Skin Neoplasms/geneticsABSTRACT
This, to our knowledge, is the first documented report of eczema herpeticum due to infection with herpesvirus hominis type 2. The virus was isolated from a patient with known Darier disease who developed Kaposi varicelliform eruption. Recent increases in the incidence of infection with type 2 herpes simplex as well as the high frequency of recurrence with this virus make this infection of potential significance in patients with preexisting cutaneous disease.
Subject(s)
Darier Disease/complications , Herpesviridae Infections/complications , Kaposi Varicelliform Eruption/etiology , Adult , Herpesviridae Infections/diagnosis , Humans , Kaposi Varicelliform Eruption/complications , Kaposi Varicelliform Eruption/diagnosis , MaleSubject(s)
Glucose/metabolism , Glucosephosphate Dehydrogenase Deficiency/metabolism , Adult , Black or African American , Blood Glucose/analysis , Cortisone , Glucose/administration & dosage , Glucose Tolerance Test , Glucosephosphate Dehydrogenase Deficiency/blood , Humans , Injections, Intravenous , Insulin/blood , Male , Methods , Time FactorsABSTRACT
In view of the problems caused by the chloroquine-resistance of some strains of Plasmodium falciparum, the authors have investigated the effectiveness of diaphenylsulfone against two such resistant strains, from Malaya and Viet-Nam. They found that diaphenylsulfone given during acute attacks of malaria had a blood schizontocidal activity against the Malayan resistant strain but was not rapidly effective in terminating acute attacks in non-immune persons, and that, when the drug was given prophylactically in relatively small doses, it was substantially effective in preventing patency of mosquito-induced infection with the same strain. The protective effect of diaphenylsulfone is that of a clinical prophylactic or suppressive drug; it does not appear to be a true causal prophylactic. It was also found that the protective effect is vitiated by the concurrent administration of paraaminobenzoic acid.These studies indicate a need for further assessment of the antimalarial value of sulfones and sulfonamides, both alone and in combination with other drugs, for prevention and cure.
Subject(s)
Dapsone/therapeutic use , Malaria/drug therapy , Adult , Aminobenzoates/pharmacology , Drug Resistance, Microbial , Humans , Male , Plasmodium falciparum/drug effectsABSTRACT
The need to investigate further the phenomenon of sulfone-induced haemolysis is becoming greater as the use of sulfones may increase, particularly for malaria therapy in areas where Plasmodium falciparum is found to be resistant to chloroquine. The authors report on studies of the haemolytic effects of diaphenylsulfone (DDS) administered orally, in doses ranging from 25 mg to 300 mg daily for 21 days, to normal healthy men and to healthy Negro men with deficiency of glucose-6-phosphate dehydrogenase (G-6-PD). The latter proved more susceptible to diaphenylsulfone-induced haemolysis than did normal men. There was a direct relationship between the dose of diaphenylsulfone and the extent of haemolysis in both groups of men studied. Comparison of the haemolytic effects of diaphenylsulfone with those of the antimalarial drug primaquine revealed that, on a dose for weight basis, diaphenylsulfone is more haemolytic than primaquine in normal persons and less so in G-6-PD-deficient persons. A marked decrease in the content of reduced glutathione (GSH) in red cells, comparable to the changes in levels of erythrocytic GSH known to occur during primaquine-induced haemolysis, occurred just before and early during the acute haemolytic episode that resulted from administration of diaphenylsulfone to G-6-PD-deficient subjects; in contrast, levels of erythrocytic GSH increased early during the course of diaphenylsulfone-induced haemolysis in normal men.
